Myelodysplasia (MDS): Symptoms, Diagnosis and Treatment

Myelodysplasia can be a confusing word to find on a blood-test referral or a specialist’s letter. This guide explains what it usually means in adult blood-cancer care, how a diagnosis is established, what risk scores can and cannot tell you, and how treatment decisions connect with everyday life. It is general education, not an individual diagnosis or treatment plan.

Information checked October 15, 2026. Discuss your circumstances with a qualified healthcare professional and read our medical disclaimer.

What is myelodysplasia?

Myelodysplasia commonly refers to myelodysplastic syndromes, abbreviated MDS. These are cancers affecting the blood-forming cells in bone marrow. Abnormal cells do not develop into enough healthy, functioning blood cells, so problems can arise from shortages of red cells, infection-fighting white cells or platelets. MDS is a group of conditions with different courses, rather than one disease that behaves identically in everyone. Some cases progress to acute myeloid leukemia, or AML, while others do not. The diagnosis therefore starts a more detailed assessment: which cells are affected, how the marrow looks, and which disease features matter for the person’s treatment. The word alone cannot tell you how urgently treatment is needed. ¹

Why records may say syndrome or neoplasm

The World Health Organization’s fifth-edition classification uses myelodysplastic neoplasms while retaining the familiar abbreviation MDS. Neoplasm describes abnormal new cell growth; the change emphasizes the cancerous nature of these disorders. Modern classification brings together what cells look like and their genetic characteristics. Some groups are defined by changes such as an isolated deletion of part of chromosome 5’s long arm, an SF3B1 mutation or biallelic TP53 inactivation. Other groups depend more on the marrow appearance and the proportion of immature cells. These names are not interchangeable descriptions of severity. Ask for the complete diagnostic name from the pathology report and which classification system was used. A newer name in a letter may reflect updated terminology rather than a new change in the illness itself. ³

Symptoms and reasons to get checked

MDS may first appear as an unexpected abnormal blood count, with no obvious symptoms. When symptoms develop, they can include persistent tiredness or weakness, breathlessness with light activity, frequent infections, or taking longer to recover from illness. Unusual bruising, nosebleeds, bleeding gums and heavier periods can also occur. Some people look paler than usual, although this is harder to recognize on darker skin. None of these findings establishes MDS by itself. Many other conditions cause similar problems, so the useful next step is medical assessment rather than trying to diagnose the cause from a symptom list. An urgent referral means that further investigation is needed; it does not by itself confirm cancer. ²

Causes, age and family history

MDS involves changes in the DNA of blood-forming cells. In most people these changes arise during life, and no single trigger can be identified. The condition becomes more common with increasing age, but age is not a rule that excludes younger adults. Previous chemotherapy or radiotherapy can increase risk, and prolonged exposure to certain chemicals, including benzene, is another recognized risk factor. A history of cancer treatment is therefore important to share with the hematology team. Having a risk factor does not prove what caused an individual case. Most MDS is not inherited, although inherited predispositions do exist. People should not assume that the diagnosis means they caused their illness or that their children will necessarily develop it. ⁵

A genetic change found in marrow cells and a genetic change inherited throughout the body are different findings. When the history or laboratory results suggest an inherited predisposition, specialists may recommend genetic counseling and additional testing. Clues can include a relevant family history, longstanding blood-count problems or particular molecular findings; the assessment requires expertise rather than a home checklist. Establishing an inherited predisposition can affect treatment planning and the choice of a stem-cell donor. A relative who appears healthy may still carry a relevant variant, so being related does not automatically make someone an appropriate donor. Counseling also addresses what a result could mean for relatives and how to approach testing with informed consent. ⁹

How MDS is investigated

What a complete blood count can show

A complete blood count, also called a full blood count, measures several different components. Hemoglobin helps describe the blood’s oxygen-carrying capacity. The platelet count relates to the cells that help stop bleeding. A white-cell differential separates the white cells into their different types, which is more informative than the total alone when considering infection defenses. Mean corpuscular volume, or MCV, describes average red-cell size. A result outside the laboratory range is a clue, not a diagnosis. Clinicians interpret it alongside symptoms, medicines, medical history and other tests. Keep the units, reference range and collection date with each result: numbers copied without that context can be misleading, especially when comparing reports from different laboratories. ⁶

Bone-marrow aspiration and biopsy

A marrow aspiration collects liquid marrow and cells; a biopsy collects a small core of marrow tissue and bone. They are often performed together, usually from the back of the hip. Local anesthetic is used, and sedation options depend on the service and the person’s needs. Pressure or brief pain can still occur, so ask what comfort measures are available instead of assuming the procedure must be painless. Tell the team about medicines and bleeding problems before the appointment, and follow its instructions without stopping a prescription independently. Afterward, ask how to care for the site and which symptoms need a call. Results may arrive in stages because several laboratory investigations can be performed on the same sample. ⁷

Microscopy, chromosomes and molecular testing

The laboratory examines the size, shape and maturity of blood and marrow cells. It also counts blasts, which are very immature cells. Chromosome studies, sometimes described as cytogenetics or a karyotype, look for larger changes in genetic material. Other tests examine selected genes or use techniques such as fluorescence in situ hybridization to answer more specific questions. These tests are complementary: one normal result does not necessarily settle everything the other tests are investigating. Genetic findings can help identify the disease type, inform prognosis or point toward a treatment that fits a particular alteration. Ask which results are final, which are still pending, and whether a later result could change the current working diagnosis or treatment discussion. ⁸

Why an abnormal result is not always MDS

Other explanations must be assessed before low blood counts are attributed to MDS. Depending on the findings, clinicians may check vitamin B12 and folate, review medicines and alcohol exposure, or investigate infection, immune conditions and other marrow disorders. Treatable deficiencies can resemble parts of the MDS picture, but taking supplements without establishing a deficiency does not replace the diagnostic workup. ³⁴

Specialists must distinguish MDS from other causes of low blood counts and from related clonal conditions. A mutation can sometimes be present without the full features required for MDS, as in clonal hematopoiesis or clonal cytopenia of undetermined significance. Conversely, diagnostic classification may depend on a combination of persistent cytopenias, morphology and defining genetic changes. The boundary with AML also has exceptions to simplified blast-count rules. The International Consensus Classification includes an MDS/AML category for certain adult cases with 10–19% blasts, and particular genetic abnormalities can influence classification. Do not use an online cutoff to overturn a pathology diagnosis. Ask the hematologist to explain how the complete findings fit the classification being used and whether expert pathology review would help. ⁴

Understanding risk scores and prognosis

The Revised International Prognostic Scoring System, or IPSS-R, combines marrow blast percentage, chromosome findings and the severity of reduced hemoglobin, platelets and neutrophils. It places patients into five risk groups, ranging from very low to very high. Older IPSS labels such as intermediate-1 and intermediate-2 are different categories, not direct equivalents of IPSS-R or IPSS-M groups. The model was developed using a large international population of people with untreated MDS. Its purpose is to distinguish patterns of disease behavior and support clinical decisions, not to provide a personal expiry date. Published survival figures describe groups treated in particular settings and periods. They do not incorporate every later treatment or every individual health circumstance. Ask which score has been calculated, when its inputs were collected, and how your clinician is using the result alongside your current symptoms and general health. ¹⁰

The Molecular International Prognostic Scoring System, or IPSS-M, adds mutation information from 31 genes to clinical and chromosome data. It organizes risk into six categories and can move someone into a different category from the one assigned by IPSS-R. This is one reason a consultation after molecular testing may sound different from the first discussion. The score reflects a combination of findings; an isolated mutation name should not be interpreted without its context. Missing molecular information can also affect the certainty of the assessment. Ask whether the required testing was available and whether the team considers the score sufficiently complete for the decision at hand. A change in estimated risk should be explained in terms of what it changes about monitoring, treatment or transplant evaluation. ¹¹

Treatment planning: what is the goal?

For lower-risk MDS, treatment often concentrates on improving symptoms, reducing transfusion needs and maintaining quality of life. Higher-risk MDS more often calls for treatment intended to control the disease and improve survival, with early consideration of transplantation in suitable patients. Supportive care continues alongside disease-directed treatment; the two approaches are complementary. The balance also depends on other illnesses and the person’s priorities. Some lower-risk patients have features that justify more intensive evaluation, while some higher-risk patients cannot tolerate intensive treatment. A risk label therefore guides the conversation without replacing an individualized plan. ³⁴

Some people with MDS and relatively stable counts or few symptoms do not need immediate drug treatment. Active monitoring, sometimes called watch and wait, involves planned examinations and blood tests rather than leaving the condition unattended. The team looks for changes in counts, symptoms and disease behavior that would make treatment worthwhile. Avoiding unnecessary treatment can spare someone adverse effects while the disease remains stable. The important practical question is what would trigger a change in the plan. Agree on the next review, how results will be communicated and what to report between appointments. If new symptoms occur, contact the service rather than waiting simply because a routine appointment is already booked. ¹²

At the start of a treatment discussion, ask the team to finish one sentence: “The main goal of this treatment for me is…” The answer might focus on symptoms, time spent receiving care, transfusion needs, disease control or preparation for another treatment. Write that goal alongside the proposed schedule and the review date. Then ask what improvement would look like, what trade-offs are expected and which alternatives remain available. This makes it easier to compare options that require very different amounts of time and support. Tell the team about work, caring responsibilities, transport and the activities that matter most to you. Those details belong in the decision, rather than appearing only after a plan becomes difficult to follow.

Supportive care and treatment for anemia

Red-cell and platelet transfusions

Transfusions provide healthy donated blood components through an intravenous line. Red-cell transfusions can help when red-cell levels are too low; platelet transfusions address a different shortage. Needs vary widely, from occasional support to regular appointments, and platelet benefits may be short-lived. Transfusions support blood-cell levels without replacing the underlying marrow problem. Ask which component is planned and how its benefit will be assessed. A written transfusion record can help keep dates and products clear across services. If a relative offers to donate blood directly, discuss this with the hematology team first, especially when a future family stem-cell donor is a possibility. The transfusion service needs to coordinate those decisions rather than treating every potential donation as interchangeable. ¹³

Erythropoiesis-stimulating agents

Erythropoiesis-stimulating agents, or ESAs, include epoetin and darbepoetin. They can be used to encourage red-cell production in selected people with lower-risk MDS. Baseline erythropoietin levels and existing transfusion needs help clinicians judge the likelihood of benefit. In a randomized study of 147 people with lower-risk MDS, anemia and a relatively low transfusion burden, darbepoetin reduced the proportion needing transfusions during the study’s main assessment period compared with placebo. That finding supports a role in carefully selected patients; it does not mean every person with anemia will respond. The study did not establish a cure or a universal survival benefit. Ask what response is being sought and how the team will decide whether continuing the treatment is worthwhile. ¹⁴

Luspatercept

Luspatercept is an erythroid maturation agent used for certain forms of MDS-associated anemia. Current United States labeling includes adults with very low- to intermediate-risk MDS who have not previously received an ESA and may need regular red-cell transfusions. A separate labeled indication covers certain patients whose anemia has not responded to an ESA and who have ring sideroblasts and need at least two red-cell units over eight weeks. These are distinct eligibility routes, which is why older descriptions can be incomplete. Luspatercept is not a substitute for a transfusion when anemia needs immediate correction. Treatment requires review of hemoglobin, transfusion history and adverse effects, including blood-pressure concerns. Ask which indication applies, what benefit would justify continuing, and how the treatment fits with other available options locally. ¹⁵

Imetelstat

Imetelstat is a telomerase inhibitor approved in the United States for adults with low- to intermediate-1-risk MDS and transfusion-dependent anemia requiring at least four red-cell units over eight weeks, after ESA failure, loss of response or ineligibility. In the randomized IMerge trial, more people receiving imetelstat achieved periods without red-cell transfusions than those receiving placebo; both groups received supportive care. A transfusion-free interval is a meaningful outcome, but it is different from proving that the disease has been cured. Low platelets, low neutrophils and other laboratory abnormalities were important adverse effects. Eligibility, infusion visits and monitoring need to be considered together. Ask about the expected chance and duration of benefit rather than assuming approval guarantees an individual response. ¹⁶

Lenalidomide and chromosome 5q deletion

Lenalidomide has a specific role in transfusion-dependent anemia associated with lower-risk MDS carrying a deletion of part of chromosome 5, commonly written del(5q). The precise chromosome findings matter; the drug is not a general replacement for every anemia treatment. Its prescribing information warns about significant reductions in neutrophils and platelets, so blood-count monitoring is essential. It can also cause severe harm to a developing fetus and is supplied under a restricted safety program in the United States. Reproductive precautions must be discussed when relevant, even if the appointment’s main focus is blood counts. Ask the prescriber and pharmacist to explain the required monitoring and safety arrangements. Do not share this medicine or change the schedule without the treating team’s instructions. ¹⁷

Iron overload and chelation

Repeated red-cell transfusions can lead to iron accumulation, and a specialist may consider an iron-removing medicine in selected circumstances. Deferasirox is one such medicine, but treating iron overload is not a routine instruction to take it after a fixed number of transfusions. Its labeling includes serious warnings about kidney injury, liver failure and gastrointestinal bleeding. Certain patients, including those with high-risk MDS or very low platelets, are not suitable under the label’s restrictions. The potential benefit must be weighed against these risks and the wider treatment plan. Ask what evidence of iron overload is being assessed, what monitoring is needed and what would prompt a change. Chelation should not be started from an isolated ferritin result or an online recommendation. ²⁸

Treatment directed at the MDS itself

Azacitidine and careful monitoring

Azacitidine is a hypomethylating medicine used to treat MDS. The injectable product is administered in repeated treatment cycles, and several cycles may be needed before its benefit is clear. Treatment can reduce blood-cell counts as well as cause problems such as nausea or injection-site reactions, making regular monitoring part of the treatment rather than an optional extra. Kidney and liver considerations also influence safe use. The prescribing information specifically warns against substituting oral azacitidine for injectable azacitidine because the products are not interchangeable. Ask the team to identify the exact formulation and explain how response will be evaluated. Report troublesome effects promptly; a clinician may adjust treatment, but a patient should not interpret one difficult cycle as a reason to stop independently. ¹⁸

Decitabine and an oral combination

Decitabine is another hypomethylating treatment. An oral product combines decitabine with cedazuridine, which helps achieve the intended exposure to decitabine. Taking treatment at home does not remove the need for laboratory checks, infection precautions or a carefully followed schedule. The United States label distinguishes its MDS or CMML monotherapy indication from its separate combination use with venetoclax for selected newly diagnosed AML patients. An AML approval should not be read as an automatic approval of the same combination for MDS. The label also cautions against exchanging the oral product with intravenous decitabine within a cycle. Ask for written instructions about the exact product, planned blood tests and whom to call about missed or vomited doses, rather than improvising a replacement dose. ¹⁹

Mutation-targeted treatment

Ivosidenib illustrates how molecular testing can open a specific treatment option. In the United States it is approved for adults with relapsed or refractory MDS carrying a susceptible IDH1 mutation identified with an approved test. Relapsed means the disease has returned after a response; refractory means it has not responded adequately. The approval was based on a small, single-arm study of 18 adults, so its results should not be generalized to all MDS or compared casually with larger randomized trials. Important risks include differentiation syndrome and changes in the heart’s electrical rhythm. The treating service must explain monitoring and symptoms that need urgent attention. A mutation report is the beginning of an eligibility discussion, not permission to obtain or start a targeted drug independently. ²⁰

Stem-cell transplantation: potential benefit and real risks

Allogeneic transplantation uses blood-forming stem cells from a donor and remains the established potentially curative approach for MDS. Whether and when it is appropriate depends on both disease-related risk and the person’s health, functional status, other illnesses, donor options and goals. Updated EBMT recommendations emphasize considering transplant eligibility after the diagnosis is confirmed and making the decision through a shared discussion. Referral for assessment does not commit someone to a transplant. It can clarify options while there is time to plan. Lower-risk disease does not automatically require immediate transplantation, and older age alone is not the entire eligibility assessment. Ask the transplant team to compare the risks of proceeding now with the risks of waiting or using another treatment. ²¹

Evidence for transplantation includes a prospective study of people aged 50–75 with advanced MDS who were assigned to donor or no-donor groups according to donor availability. The donor group had better overall survival at three years. This supports considering reduced-intensity transplantation in suitable older adults, rather than dismissing it solely because of age. However, biological assignment by donor availability is not the same as a conventional randomized drug trial, and participants had already been judged potential transplant candidates. The findings cannot promise the same outcome to someone with substantially different health or disease features. Ask how closely the study population resembles your circumstances, and request an individualized explanation of transplant-related risk as well as the chance of controlling MDS. ²²

A stem-cell transplant is a sequence of treatment and recovery, not an operation in which a new marrow organ is surgically installed. Donor cells are infused into a vein and travel to the marrow. Preparatory treatment, immune suppression and the period before blood-cell recovery can create substantial infection and bleeding risks. With an allogeneic transplant, graft-versus-host disease can occur when donor immune cells attack the recipient’s tissues. Recovery and immune rebuilding take time, and follow-up continues after leaving hospital. Ask about the likely admission or outpatient arrangements, caregiver responsibilities, distance from the center and long-term monitoring. Knowing these practical demands helps a family assess what support will be needed before agreeing to a plan. ²³

Infection and bleeding: when waiting is unsafe

Low neutrophils and some cancer treatments increase the risk that an infection becomes serious quickly. Fever, chills, a new cough, painful urination, diarrhea, mouth changes or redness around a catheter can warrant urgent contact with the treating service. Get a written temperature threshold and instructions for nights and weekends; follow any more cautious threshold your own team gives. Ask before using fever-reducing medicines, because they can hide a warning sign without treating the cause. Regular handwashing, careful catheter and mouth care, and avoiding close contact with people who are ill are practical precautions. Preventive medicines may be appropriate for some people, but the need depends on the treatment and infection risk. Do not borrow antibiotics or wait for a routine blood test to report a concerning illness. ²⁴

Low platelets can make bruising and bleeding more likely. Tell the team about new pinpoint red or purple spots, increasing bruises, bleeding gums or nosebleeds. Review over-the-counter pain medicines and supplements, because products containing aspirin or ibuprofen can increase bleeding risk. Do not stop a prescribed blood thinner on your own; ask the responsible clinician how the competing risks should be managed. Gentle toothbrushing, care with sharp objects and avoiding injuries are sensible precautions when the team advises them. Ask what to do if bleeding starts and which situations require emergency care. A platelet number is only part of that conversation: symptoms, medicines and the planned procedure also matter. ²⁵

For background on a symptom discussed above, see our guide to blood in stool. It does not replace the urgent-contact instructions from your hematology team.

Everyday care during monitoring or treatment

Food safety and useful nutrition questions

When immunity is weakened, foodborne infections can be more serious. Choose safely cooked meat, eggs and seafood, pasteurized dairy products and washed produce. Raw sprouts, undercooked animal foods and unpasteurized products can carry avoidable risks. Safe handling matters as much as choosing a food: keep preparation surfaces clean, separate raw meat from ready-to-eat foods, cook thoroughly and refrigerate promptly. A food thermometer is more reliable than appearance alone for checking cooking. Ask whether your treatment center has additional instructions for your situation, especially around transplantation. If nausea, poor appetite or a restrictive diet makes adequate eating difficult, request dietetic help. The aim is a practical eating plan that supports nutrition while reducing exposure to foodborne germs, rather than an unsupported list of foods claimed to cure MDS. ²⁶

Vaccination planning

Vaccination should be reviewed with the cancer team early, ideally before treatment starts when possible. The appropriate vaccines and timing depend on age, previous doses, the treatment and the state of immune recovery. ASCO guidance distinguishes nonlive vaccines from live vaccines, which can be unsuitable during significant immune suppression. Stem-cell transplantation can require a planned course of revaccination because previous protection may be lost. Household members’ recommended vaccinations also matter, with precautions for particular vaccines and circumstances. Bring whatever vaccination record you have rather than guessing dates. Do not assume that advice given before transplantation still applies afterward, or that every vaccine must be postponed until all treatment is over. Ask the team to coordinate a current plan with your usual healthcare provider. ²⁷

Fatigue, activity and daily function

Cancer-related fatigue can affect concentration, motivation and the ability to manage ordinary tasks. It can have several contributors, including treatment effects, anemia, poor sleep, pain or emotional distress, so reporting it is more useful than simply labeling it inevitable. Describe what has changed: walking distance, time needed to recover after activities, sleep quality or ability to prepare meals. A clinician can assess treatable contributors and discuss an appropriate balance of rest and activity. Gentle movement can help some people, but the plan should fit current symptoms and medical restrictions. Keep demanding tasks for times when energy is better and accept help with practical chores. A diary of fatigue and treatment days can make the discussion more specific than a single tiredness rating. ²⁹

Clinical trials and additional support

A clinical trial tests a defined research question using a written protocol and eligibility criteria. Ask about relevant trials when discussing options, including what the comparison treatment is and what is already known about risks and potential benefit. Participation is voluntary, and informed consent is an ongoing discussion rather than just a signature. You can ask questions and withdraw, although the team should explain how to do so safely. Some costs may be covered by the sponsor or insurance, while travel, parking, accommodation or other expenses may remain. Request a clear breakdown before committing. A trial listing does not mean enrollment is guaranteed or that the experimental treatment is better; it provides a starting point for a discussion with the research team. ³⁰

Palliative care focuses on symptoms, quality of life and the practical or emotional effects of serious illness. It can be provided alongside treatment intended to control cancer and is not limited to the final days of life. A palliative-care team may help with pain, sleep, distress, difficult decisions and communication among clinicians and family members. It can also help clarify what matters most when the burdens and benefits of treatment are finely balanced. Asking for this support does not mean abandoning hematology care. Explain which problems are hardest to live with and ask whether a referral would be useful. Support should be shaped around the person and family, rather than reserved only for a particular disease stage or treatment outcome. ³¹

A diagnosis can bring fear, anger, sadness or uncertainty, and those feelings may change over time. Different people prefer different forms of support: a trusted friend, a counselor, a faith community or a group of people with similar experiences. There is no requirement to remain upbeat to deserve help. Tell the team if worry, low mood or disrupted sleep is interfering with daily life, especially when symptoms persist. Physical symptoms should not automatically be attributed to anxiety, because medicines and illness can produce overlapping effects. Ask the nurse or social worker about practical resources as well as emotional support. Help with transport, costs or communication can make the care plan more manageable alongside professional help for distress. ³²

Preparing for your next hematology appointment

Bring the latest medication list, questions you most want answered and any records that another service may not have shared. If possible, keep a concise timeline of appointments, blood tests, transfusions and treatment changes, with the dates written clearly. Ask permission before recording the conversation, or invite a trusted person to take notes. At the end, repeat back the main plan in your own words: what happens next, who arranges it and when you should expect an update. If the explanation is unclear, ask for it again in simpler language. Before leaving, make sure you have a contact route that works outside normal clinic hours and know where the written instructions are stored.

Frequently asked questions

Is myelodysplasia the same as MDS?

In adult blood-cancer care, myelodysplasia commonly means myelodysplastic syndrome, abbreviated MDS. Ask your clinician to confirm the exact diagnosis. ²

Is MDS usually inherited?

Most MDS is not inherited. A minority of cases involve an inherited predisposition that may warrant genetic counseling. ⁵

Can a blood test alone diagnose MDS?

Blood counts can raise suspicion, but diagnosis usually also requires marrow examination and other laboratory findings. ⁸

Does everyone need treatment immediately?

No. Some people can have active monitoring with regular checks until symptoms or disease changes make treatment appropriate. ¹²

Can a stem-cell transplant cure MDS?

Donor transplantation is potentially curative, but it has serious risks and is not suitable for everyone. ²¹

Educational background video retained from the original article; not assessed in full. Terminology and treatment details may differ from current guidance. Discuss diagnosis and treatment decisions with a qualified healthcare professional.